Amgen’s Biosimilar Revenue Boosted by $150 Million in Sales of J&J Copycat Drug in Q1
Amgen’s biosimilar business experienced a surge in revenue, driven in part by $150 million in first-quarter sales of its copycat version of Johnson & Johnson’s blockbuster medicine. The company’s biosimilar product, a direct competitor to a major Johnson & Johnson drug, contributed significantly to the overall growth of Amgen’s biosimilar division during the first three months of the year.
Newsflash | Powered by GeneOnline AI
Date: May 2, 2025
LATEST
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15